Top in rheumatology: JAK inhibitor risks; erosive hand osteoarthritis
Click Here to Manage Email Alerts
A speaker at the American College of Rheumatology’s annual conference reviewed data on the association between Janus kinase inhibitors and elevated risks for cardiovascular events and malignancy.
These risks have led to black-box warnings for Janus kinase (JAK) inhibitors with indications for arthritis and other inflammatory conditions, John Giles, MD, MPH, an associate professor of medicine at Columbia University, said.
He encouraged physicians to discuss these risks with patients and said that “screening and risk mitigation consistent with regulatory warnings is advisable.” It was the top story in rheumatology last week.
Another top story was about new data on Prolia (denosumab, Amgen) that showed it induced structural modifications in patients with erosive hand osteoarthritis. Researchers said they found no new safety concerns associated with the drug.
Read these and more top stories in rheumatology below:
JAK inhibition’s cardiovascular, malignancy risks are a ‘moving target’
Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022. Read more.
Denosumab achieves structural modification in erosive hand osteoarthritis
Denosumab successfully induces structural modifications patients with active erosive hand osteoarthritis, data show. Read more.
‘Can’t be in 10 places at once’: Social media now a key part of rheumatology meetings
COVID-19 was in so many ways an inflection point for nearly all aspects of health care, with one of the most conspicuous, continuing examples of “pre-2020” differing from “post-2020” being the way people consume data from meetings. Read more.
Clinicians ‘never too old or too young’ to use social media
Understanding the social media landscape can help rheumatologists learn about patients and connect more effectively with them, according to a presenter. Read more.
Bimekizumab shows long-term efficacy, tolerability in psoriatic arthritis
Interleukin-17 inhibition with bimekizumab yields strong joint and skin effects up to week 52 in patients with active psoriatic arthritis, data show. Read more.